Vitamin D* (n=28) | Placebo (n=15) | |
Demographics | ||
Age, years | 34.5 (29.5–45.0) | 37.0 (30.0–50.0) |
Female | 92.9 | 93.3 |
Race | ||
White | 32.1 | 60.0 |
Black | 53.6 | 40.0 |
Other | 14.3 | 0 |
SLE characteristics | ||
Disease duration, years | 8.0 (3.9–14.2) | 10.0 (3.3–16.0) |
ANA positive | 96.4 | 86.7 |
Anti-double stranded DNA positive | 92.9 | 93.3 |
Renal disorder | 35.7 | 40.0 |
SELENA-SLEDAI score | 3 (2–4) | 4 (2–4) |
Interferon gene signature detectable | 89.3 | 73.3 |
Laboratory values | ||
CTX, mg/L | 80.0 (34.0–118.5) | 76.0 (64.0–147.0) |
P1NP, μg/L | 45.2 (31.8–62.2) | 48.9 (31.5–74.3) |
Serum 25-hydroxyvitamin D, ng/mL | 11.9 (10.1–14.4) | 9.9 (6.9–14.5) |
Medications | ||
Glucocorticoids, prednisone equivalent | ||
0 mg/day | 57.1 | 66.7 |
>0 to <7.5 mg/day | 25.0 | 20.0 |
≥7.5 mg/day | 17.9 | 13.3 |
Antimalarial | 60.7 | 80.0 |
Azathioprine | 25.0 | 6.7 |
Methotrexate | 14.3 | 0 |
Mycophenolate | 32.1 | 33.3 |
Bisphosphonate | 10.7 | 6.7 |
Presented as median (IQR) or %.
*2000 IU daily (low dose) or 4000 IU daily (high dose).
CTX, C-telopeptide; P1NP, N-terminal propeptide of type 1 collagen; SELENA-SLEDAI, Safety of Estrogens in Lupus National Assessment-SLE Disease Activity Index.